Aurinia Pharmaceuticals Stock Price - AUPH

0.18 (0.88%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Aurinia Pharmaceuticals Inc AUPH NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.01 0.05% 20.37 19.92 20.4794 20.36 20.36 20:00:00
Bid Price Ask Price Spread Spread % News
20.25 20.90 0.65 3.11% - 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
6,566 1,121,492 $ 20.14 $ 22,583,007 1,530,026 3.52 - 21.93
Last Trade Time Type Quantity Stock Price Currency
18:50:36 formt 180 $ 20.55 USD

Aurinia Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 2.22B 109.07M $ -64.12M - - 111.80M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Aurinia Pharmaceuticals News

Loading Messages....

Latest AUPH Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical AUPH Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week19.0720.479418.3519.801,347,0121.306.82%
1 Month19.1120.479417.1818.991,349,6811.266.59%
3 Months7.2321.937.1517.143,512,23513.14181.74%
6 Months5.9021.933.5213.722,228,66514.47245.25%
1 Year6.3221.933.5212.281,394,96914.05222.31%
3 Years3.8221.933.238.261,732,49816.55433.25%
5 Years3.9021.931.427.251,300,52116.47422.31%

Aurinia Pharmaceuticals Description

Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.

Your Recent History
Aurinia Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.